Propensity-weighted Long-term Risk of Urinary Adverse Events After Prostate Cancer Surgery, Radiation, or Both

被引:79
作者
Jarosek, Stephanie L. [1 ]
Virnig, Beth A. [2 ]
Chu, Haitao [3 ]
Elliott, Sean P. [1 ]
机构
[1] Univ Minnesota, Sch Med, Dept Urol, Minneapolis, MN 55455 USA
[2] Univ Minnesota, Sch Publ Hlth, Div Hlth Policy & Management, Minneapolis, MN 55455 USA
[3] Univ Minnesota, Sch Publ Hlth, Div Biostat, Minneapolis, MN 55455 USA
关键词
Outcomes research; Prostate cancer; Reconstructive urology; SEER-Medicare; Urinary adverse effects; MARGINAL STRUCTURAL MODELS; DOSE-RATE BRACHYTHERAPY; SEER-MEDICARE DATA; RADICAL PROSTATECTOMY; COMPLICATIONS; RADIOTHERAPY; THERAPY; MORBIDITY; GENITOURINARY; POPULATION;
D O I
10.1016/j.eururo.2014.08.061
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Prostate cancer is the second most common cancer in men and has high survivorship, yet little is known about the long-term risk of urinary adverse events (UAEs) after treatment. Objective: To compare the long-term UAE incidence across treatment and control groups. Design, setting, and participants: Using a matched-cohort design, we identified elderly men treated with external-beam radiotherapy (EBRT; n = 44 318), brachytherapy (BT; n = 14 259), EBRT+BT (n = 11 835), radical prostatectomy (RP; n = 26 970), RP+EBRT (n = 1557), or cryotherapy (n = 2115) for non-metastatic prostate cancer and 144 816 non-cancer control individuals from the population-based Surveillance, Epidemiology, and End Results-Medicare linked data from 1992-2007 with follow-up through 2009. Outcome measures and statistical analysis: The incidence of treated UAEs and time from cancer treatment to first UAE were analyzed in terms of propensity-weighted survival. Results: Median follow-up was 4.14 yr. At 10 yr, all treatment groups experienced higher propensity-weighted cumulative UAE incidence than the control group (16.1%; hazard risk [HR] 1.0), with the highest incidence for RP+EBRT (37.8%; HR 3.19, 95% confidence interval [CI] 2.79-3.66), followed by BT+EBRT (28.4%; HR 1.97, CI 1.85-2.10), RP (26.6%; HR 2.44, CI 2.34-2.55), cryotherapy (23.4%; HR 1.56, CI 1.30-1.87), BT (19.8%; HR 1.43, CI 1.33-1.53), and EBRT (19.7%; HR 1.11, CI 1.07-1.16). Bladder outlet obstruction was the most common event. Conclusions: Men undergoing RP, RP+EBRT, and BT+EBRT experienced the highest UAE risk at 10 yr, although UAEs accrued differently over extended follow-up. The significant background UAE rate among non-cancer control individuals yields a risk attributable to prostate cancer treatment that is 17% lower than prior estimates. Patient summary: We show that treatment for prostate cancer, especially combinations of two treatments such as radiation and surgery, carries a significant risk of urinary adverse events such as urethral stricture. This risk increases with time since treatment, emphasizing that treatments have long-term effects. (C) 2014 European Association of Urology. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:273 / 280
页数:8
相关论文
共 50 条
  • [1] Propensity-Weighted Comparison of Long-Term Risk of Urinary Adverse Events in Elderly Women Treated For Cervical Cancer
    Elliott, Sean P.
    Fan, Yunhua
    Jarosek, Stephanie
    Chu, Haitao
    Downs, Levi
    Dusenbery, Kathryn
    Geller, Melissa A.
    Virnig, Beth A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 92 (03): : 586 - 593
  • [2] Inverse probability of treatment-weighted competing risks analysis: an application on long-term risk of urinary adverse events after prostate cancer treatments
    Bolch, Charlotte A.
    Chu, Haitao
    Jarosek, Stephanie
    Cole, Stephen R.
    Elliott, Sean
    Virnig, Beth
    BMC MEDICAL RESEARCH METHODOLOGY, 2017, 17
  • [3] Inverse probability of treatment-weighted competing risks analysis: an application on long-term risk of urinary adverse events after prostate cancer treatments
    Charlotte A. Bolch
    Haitao Chu
    Stephanie Jarosek
    Stephen R. Cole
    Sean Elliott
    Beth Virnig
    BMC Medical Research Methodology, 17
  • [4] Perception of body odor-an overlooked consequence of long-term gastrointestinal and urinary symptoms after radiation therapy for prostate cancer
    Alsadius, D.
    Olsson, C.
    Pettersson, N.
    Tucker, S. L.
    Wilderang, U.
    Steineck, G.
    JOURNAL OF CANCER SURVIVORSHIP, 2013, 7 (04) : 652 - 658
  • [5] Understanding Long-term Urinary Adverse Events After Treatment of Localized Prostate Cancer: A Key Tool in Informed Decision-making
    Laviana, Aaron A.
    Hu, Jim C.
    EUROPEAN UROLOGY, 2015, 67 (02) : 281 - 282
  • [6] Management of Radiation Therapy Oncology Group grade 4 urinary adverse events after radiotherapy for prostate cancer
    Mayer, Erik N.
    Tward, Jonathan D.
    Bassett, Mitchell
    Lenherr, Sara M.
    Hotaling, James M.
    Brant, William O.
    Lowrance, William T.
    Myers, Jeremy B.
    BJU INTERNATIONAL, 2017, 119 (05) : 700 - 708
  • [7] Long-Term Adverse Effects and Complications After Prostate Cancer Treatment
    Unger, Joseph M.
    Till, Cathee
    Tangen, Catherine M.
    Hershman, Dawn L.
    Goodman, Phyllis J.
    LeBlanc, Michael
    Barlow, William E.
    Vaidya, Riha
    Minasian, Lori M.
    Parnes, Howard L.
    Thompson Jr, Ian M.
    JAMA ONCOLOGY, 2024, 10 (12) : 1654 - 1662
  • [8] Perception of body odor—an overlooked consequence of long-term gastrointestinal and urinary symptoms after radiation therapy for prostate cancer
    D. Alsadius
    C. Olsson
    N. Pettersson
    S. L. Tucker
    U. Wilderäng
    G. Steineck
    Journal of Cancer Survivorship, 2013, 7 : 652 - 658
  • [9] Long-term outcomes of hypofractionated radiation therapy in patients with high risk prostate cancer
    Bulychkin, P. V.
    Ekaterinushkin, D. A.
    Tkachev, S. I.
    Khachaturyan, A. V.
    Nayanov, G. B.
    Ladyko, D. D.
    Selezneva, T. D.
    ONKOUROLOGIYA, 2024, 20 (01): : 60 - 66
  • [10] Long-term use of prescription opioids for non-cancer pain and mortality: a population-based, propensity-weighted cohort study
    Hurtado, I.
    Robles, C.
    Garcia-Sempere, A.
    Llopis-Cardona, F.
    Sanchez-Saez, F.
    Rodriguez-Bernal, C.
    Peiro, S.
    Sanfelix-Gimeno, G.
    PUBLIC HEALTH, 2024, 232 : 4 - 13